# Randomized Phase III of PRRT Versus Interferon

> **NCT01860742** · PHASE3 · WITHDRAWN · sponsor: **Jules Bordet Institute**

## Conditions studied

- Gastro-intestinal Neuroendocrine Tumors

## Interventions

- **DRUG:** Interferon alpha-2b
- **DRUG:** 177Lu-DOTATATE

## Key facts

- **NCT ID:** NCT01860742
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-12
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01860742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01860742, "Randomized Phase III of PRRT Versus Interferon". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01860742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*